Re-evaluation Note REV2018-12

Re-evaluation Project Plan for Quizalofop-p-ethyl

(publié aussi en français)

8 June 2018

This document is published by the Health Canada Pest Management Regulatory Agency. For further information, please contact:

Publications
Pest Management Regulatory Agency
Health Canada
2720 Riverside Drive
A.L. 6607 D
Ottawa, Ontario K1A 0K9

Internet: canada.ca/pesticides
hc.pmra.publications-arla.sc@canada.ca
Facsimile: 613-736-3758
Information Service:
1-800-267-6315 or 613-736-3799
hc.pmra.info-arla.sc@canada.ca

Canada

ISSN: 1925-0630 (print)
1925-0649 (online)

Catalogue number: H113-5/2018-12E (print version)
H113-5/2018-12E-PDF (PDF version)

Background

In Canada, quizalofop-p-ethyl is under re-evaluation by Health Canada's Pest Management Regulatory Agency (PMRA). The PMRA re-evaluates registered pesticides to determine whether the use of these products continues to be acceptable in terms of value, human health and the environment according to current standards.

Quizalofop-p-ethyl is a selective post-emergence herbicide. It is registered in Canada for the control of annual and perennial grasses on a wide range of field food and feed crops, and industrial non-food crops, using ground or aerial application methods. Currently, there are two technical, one manufacturing concentrate, and four commercial end-use products registered in Canada.

Under the authority of section 16 of the *Pest Control Products Act*, the registrants of quizalofop-p-ethyl were notified of the initiation of the re-evaluation of quizalofop-p-ethyl. Following this, the registrants of technical grade active ingredient quizalofop-p-ethyl in Canada indicated support of all uses included on the labels of end-use products in Canada.

The re-evaluation project plan below outlines the timeline, the anticipated areas of focus for the risk assessments, and the data requirements for the re-evaluation of quizalofop-p-ethyl.

Re-evaluation Project Plan

Anticipated Re-evaluation Timeline

The re-evaluation of quizalofop-p-ethyl is defined as a Category 1 as described in Regulatory Directive DIR2016-04, *Management of Pesticides Re-evaluation Policy*, however the re-evaluation of quizalofop-p-ethyl began prior to the publication of DIR2016-04. Currently, a proposed re-evaluation decision for quizalofop-p-ethyl is anticipated to be published for consultation by June 2019. The re-evaluation timeline may be updated if, during the risk assessment, the PMRA identifies additional areas of focus that should be considered.

Human Health Risk Assessment

A new assessment will be conducted for toxicology. Existing assessments with minor updates are considered to be adequate to support the re-evaluation of quizalofop-p-ethyl for the other aspects of human health assessment.

Environmental Risk Assessment

Updated assessments will be conducted for environmental fate, water modelling and environmental exposure.

Value

The value of quizalofop-p-ethyl will be considered. The viability of alternatives will be examined for certain uses if risks of concern requiring mitigation are identified.

Data Requirements

The PMRA identified the need for the technical registrants to provide certain data for quizalofop-p-ethyl related to toxicology. Relevant data/studies were requested and received from the technical registrants. A summary of the data call-in is found in the PMRA's Public Registry, in the Pesticides section of Canada.ca. For a list of data categories that were required, see Appendix I. In addition, information regarding the registered use pattern has been requested and received from the registrants, to inform the risk assessments.

Additional Information

The PMRA documents can be found in the Pesticides section of Canada.ca. The PMRA documents are also available through the Pest Management Information Service:

Phone:	1-800-267-6315	within Canada, or
	1-613-736-3799	outside Canada (long distance charges apply)
Fax:	1-613-736-3798	
E-mail:	hc.pmra.info-arla.sc@canada.ca	

Appendix I Data Required Under Subsection 19(1) of the *Pest Control Products Act* for the Re-evaluation of Quizalofop-p-ethyl

DACO	Title
4.5.9	Metabolism/Toxicokinetics in Mammals (laboratory animals)
4.7.4	Short-term Dermal (21–28 day)
4.8	Other studies/Data/Reports
5.8	Dermal absorption (in vivo)